Proteomic identification of diabetes biomarkers

糖尿病生物标志物的蛋白质组学鉴定

• 批准号: 7127983
• 负责人: Eric J Smart
• 金额: $ 18.31万
• 依托单位: UNIVERSITY OF KENTUCKY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-07-01 至 2008-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7127983
• 关键词: adolescence (12-20); biomarker; biotechnology; blood lipoprotein metabolism; cardiovascular disorder risk; child (0-11); clinical research; diabetes risk; glucose tolerance; glucose tolerance test; high density lipoproteins; human subject; lipid raft; low density lipoprotein; monocyte; noninsulin dependent diabetes mellitus; obesity; prediabetic state; proteomics

DESCRIPTION (provided by applicant): The central hypothesis to be tested in this proposal is that the development of Type 2 diabetes induces alterations in the protein composition of lipid rafts in monocytes and in lipoproteins. Furthermore, we hypothesize that these changes will serve as biomarkers for both the development of diabetes (pre-diabetic to diabetic transition) and serve as biomarkers for the development of subsequent cardiovascular complications. The goal of this proposal is to elucidate proteins that are altered in monocyte lipid rafts and lipoproteins in patients with impaired glucose tolerance and newly diagnosed type 2 diabetics compared to patients with normal glucose tolerance. A unique aspect of this proposal is the use of pediatric patients. Type 2 diabetes has historically been an adult disease but unfortunately a large and growing number of children have type 2 diabetes. Although the mechanisms and progression of the disease appear similar in adults and children, a major difference between adult and pediatric patients is that the pediatric patients do not have as extensive co-morbidities such as atherosclerosis, renal failure, and neuropathy. A major problem in identifying biomarkers for type 2 diabetes are confounds created by patients having multiple diseases and taking multiple medications. For the most part these confound is not a major problem in pediatric patients. For these reasons, we have chosen to use pediatric patients. Three Specific Aims are proposed. Aim 1: To elucidate the complete proteome of lipid rafts in monocytes and in isolated lipoproteins (LDL and HDL) isolated from patients with normal glucose tolerance. Aim 2: To identify a subset of proteins that associate or disassociate with lipid rafts in monocytes and in lipoproteins (LDL and HDL) isolated from patients with impaired glucose tolerance. Aim 3: To characterize the proteome of lipid rafts in monocytes and in lipoproteins (LDL and HDL) isolated from newly diagnosed Type 2 diabetics.

描述（由申请方提供）：本提案中待检验的中心假设是，2型糖尿病的发生诱导单核细胞和脂蛋白中脂筏蛋白组成的改变。此外，我们假设这些变化将作为糖尿病发展（糖尿病前期向糖尿病转变）的生物标志物，并作为随后心血管并发症发展的生物标志物。本提案的目的是阐明糖耐量受损患者和新诊断的2型糖尿病患者与糖耐量正常患者相比单核细胞脂筏和脂蛋白中发生改变的蛋白质。该提案的一个独特方面是儿科患者的使用。2型糖尿病在历史上是一种成人疾病，但不幸的是，越来越多的儿童患有2型糖尿病。虽然成人和儿童的发病机制和疾病进展相似，但成人和儿童患者之间的主要差异在于儿童患者没有广泛的合并症，如动脉粥样硬化、肾衰竭和神经病变。鉴定2型糖尿病生物标志物的一个主要问题是由患有多种疾病和服用多种药物的患者造成的混淆。在大多数情况下，这些混淆不是儿科患者的主要问题。出于这些原因，我们选择使用儿科患者。提出了三个具体目标。目标1：阐明糖耐量正常患者单核细胞和分离脂蛋白（LDL和HDL）中脂筏的完整蛋白质组。目标二：鉴定与糖耐量受损患者单核细胞和脂蛋白（LDL和HDL）中脂筏结合或分离的蛋白质亚群。目的3：研究新诊断的2型糖尿病患者单核细胞和脂蛋白（LDL和HDL）中脂筏的蛋白质组特征。